floxuridine has been researched along with Breast Neoplasms in 198 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer." | 9.13 | Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008) |
| "We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy." | 9.10 | Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. ( Abe, O; Asaishi, K; Hirata, K; Ikeda, T; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Noguchi, S; Nomura, Y; Ohashi, Y; Ota, J; Sonoo, H; Sugimachi, K; Toge, T; Toi, M; Tominaga, T; Yamaguchi, S, 2003) |
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 9.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| "We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer." | 9.09 | [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001) |
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 9.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Between January 1993 and October 1995, 34 patients with anthracycline-resistant advanced breast cancer were treated with a combination chemoendocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)." | 9.08 | A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer. ( Aiba, S; Endo, K; Fujii, T; Horiguchi, J; Iino, Y; Ishida, T; Kishi, S; Kusaba, T; Maemura, M; Morishita, Y; Ohwada, S; Shiozaki, H; Sugamata, N; Takano, A; Takei, H; Takeyoshi, I; Yokoe, T; Yokomori, T, 1998) |
| "Idarubicin 29 mg/m2 was given on day 1, doxifluridine 1500 mg and prednimustine 60 mg were given daily for 10-14 days (7 days/m2) in 17 patients with advanced breast cancer." | 9.07 | Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. ( Alberto, P, 1993) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 9.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s." | 8.86 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010) |
| "Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer." | 7.78 | Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. ( Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z, 2012) |
| "We evaluated the safety and efficacy of capecitabine in 12 patients with anthracycline and/or taxane-resistant metastatic breast cancer on an outpatient basis." | 7.73 | [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N, 2005) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 7.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis." | 7.72 | [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004) |
| "Docetaxel and capecitabine are being prescribed for the treatment of breast cancer." | 7.71 | Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. ( Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001) |
| "Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective." | 7.70 | [Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 7.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 7.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy." | 7.69 | [A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 7.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 7.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 7.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 6.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases." | 6.65 | Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. ( Colsky, J; Cummings, FJ; Gelman, R; Israel, L; Kuperminc, M; Skeel, RT; Tormey, D, 1981) |
| "A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out." | 6.38 | [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992) |
| "We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy." | 5.35 | [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "Two patients were diagnosed as advanced breast cancer with multiple bone metastases." | 5.33 | [Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 5.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "She was diagnosed as having advanced breast cancer of stage T4N3 (supraclavicular lymph node) M1 (bone)." | 5.31 | [Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. ( Fujii, T; Hanaoka, T; Ishida, K; Kawashima, K; Mihara, Y; Takahashi, T, 2000) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 5.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| "Mitoxantrone (MIT) is a new anthraquinone anticancer agent." | 5.30 | [Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998) |
| "Brain metastases were also found." | 5.30 | [A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K, 1999) |
| "Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies." | 5.30 | [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999) |
| "Mitoxantrone (MIT) is a new anthraquinone anti-cancer agent." | 5.29 | [Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer]. ( Hirayama, R; Ichikawa, W; Mishima, Y; Miyanaga, T; Nihei, Z; Sawai, S; Shoji, Y; Yamashita, T; Yoshinaga, K, 1993) |
| "We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer." | 5.13 | Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008) |
| "We conducted a randomized controlled study to evaluate the safety and usefulness of a combined treatment of radiotherapy and chemotherapy with doxifluridine (5'-DFUR) plus tamoxifen (TAM) as an adjuvant therapy for breast cancer patients after conservative surgery." | 5.10 | [Assessment of complications in a randomized controlled study on multimodality therapy for patients following breast-conserving surgery: Kansai Breast Cancer Radiotherapy Research Group (5'-KBR)]. ( Hiraoka, M; Inaji, H; Inoue, T; Kodama, H; Kono, M; Kono, N; Koyama, H; Sako, M; Suzuki, R, 2002) |
| "We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy." | 5.10 | Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. ( Abe, O; Asaishi, K; Hirata, K; Ikeda, T; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Noguchi, S; Nomura, Y; Ohashi, Y; Ota, J; Sonoo, H; Sugimachi, K; Toge, T; Toi, M; Tominaga, T; Yamaguchi, S, 2003) |
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 5.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| "We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer." | 5.09 | [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001) |
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 5.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Between January 1993 and October 1995, 34 patients with anthracycline-resistant advanced breast cancer were treated with a combination chemoendocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)." | 5.08 | A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer. ( Aiba, S; Endo, K; Fujii, T; Horiguchi, J; Iino, Y; Ishida, T; Kishi, S; Kusaba, T; Maemura, M; Morishita, Y; Ohwada, S; Shiozaki, H; Sugamata, N; Takano, A; Takei, H; Takeyoshi, I; Yokoe, T; Yokomori, T, 1998) |
| "Idarubicin 29 mg/m2 was given on day 1, doxifluridine 1500 mg and prednimustine 60 mg were given daily for 10-14 days (7 days/m2) in 17 patients with advanced breast cancer." | 5.07 | Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. ( Alberto, P, 1993) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 5.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s." | 4.86 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010) |
| "Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer." | 3.78 | Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. ( Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z, 2012) |
| "The figures in patients with breast cancer were: 1,761 days (58." | 3.78 | [Survival and changes of clinical laboratory data in phase II study with 5'-DFUR]. ( Taguchi, T, 1996) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "A 42-year-old woman with multiple organ metastases from breast cancer was successfully treated with 5'-deoxy-5-fluorouridine (5'-DFUR) and hormonal therapy (leuprorelin+tamoxifen)." | 3.73 | [A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy]. ( Fukami, Y; Hasegawa, H; Hiromatsu, T; Itazu, K; Kawai, K; Komatsu, S; Sakamoto, E; Tabata, T, 2005) |
| "We evaluated the safety and efficacy of capecitabine in 12 patients with anthracycline and/or taxane-resistant metastatic breast cancer on an outpatient basis." | 3.73 | [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N, 2005) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 3.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials." | 3.72 | Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. ( Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ, 2004) |
| "We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis." | 3.72 | [Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004) |
| "Docetaxel and capecitabine are being prescribed for the treatment of breast cancer." | 3.71 | Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. ( Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001) |
| " The degree of synergism between docetaxel and two oral fluoropyrimidines, tegafur and 5'-deoxy-5-fluorouridine (5'-dFUrd), was investigated in the KPL-4 human breast cancer xenograft model." | 3.71 | Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. ( Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S, 2001) |
| "Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer." | 3.71 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. ( Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD, 2002) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| " To evaluate the mechanism of EGF-induced apoptosis, MDA-MB-468 breast cancer cells were examined by microscopy, flow cytometry, immunoblotting, enzyme assays, and affinity labeling after treatment with EGF, paclitaxel, or 5-fluoro-2'-deoxyuridine (5FUdR)." | 3.70 | Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. ( Armstrong, DK; Blajeski, AL; Davidson, NE; Earnshaw, WC; Kaufmann, SH; Kottke, TJ; Martins, LM; Mesner, PW, 1999) |
| "Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective." | 3.70 | [Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999) |
| "A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]." | 3.70 | [A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999) |
| "A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)." | 3.70 | [A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | 3.70 | Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy." | 3.69 | [A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994) |
| "A 67-year-old female with extensive inflammatory breast cancer was treated with oral chemoendocrine therapy using 5'-deoxy-5-fluorouridine (5'-DFUR) 1,200 mg and medroxyprogesterone acetate (MPA) 1,200 mg before intra-arterial infusion chemotherapy, which made the extensive inflammatory skin lesion improve remarkably." | 3.69 | [A case of inflammatory breast cancer successfully treated with 5'-DFUR and MPA]. ( Ebihara, Y; Hirota, T; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Sekine, M; Serizawa, H, 1994) |
| "Twelve patients with liver metastases of breast cancer were treated with hepatic arterial infusion chemotherapy using 20-30 mg/body of epi-adriamycin (epi-ADM) every 2 weeks and continuous infusion of 250 mg/body/day of 5-fluorouracil (5-FU)." | 3.69 | [Intra-arterial infusion chemotherapy for liver metastases from breast cancer]. ( Furukawa, J; Kinuta, M; Maruhashi, S; Maruyama, H; Masuda, N; Matsui, S; Okamura, J; Ooi, H; Takiguchi, S; Tateishi, H; Tokunaga, M; Yano, H; Yayoi, E, 1996) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 3.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i." | 3.69 | [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997) |
| "An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA." | 3.68 | [5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991) |
| "We have studied the effects of methotrexate (MTX-Glu1) and the polyglutamate derivatives of methotrexate (MTXPGs) with 2, 3, 4, and 5 glutamyl residues on the catalytic activity of thymidylate synthase purified from MCF-7 human breast cancer cells and on the kinetics of the ternary complex formation by 5-fluoro-2'-deoxyuridine 5'-monophosphate, folate cofactor, and thymidylate synthase." | 3.67 | Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. ( Allegra, CJ; Chabner, BA; Drake, JC; Jolivet, J; Lutz, R; Rodbard, D, 1985) |
| "We have investigated the role of dihydrofolate (H2PteGlu) accumulation in the inhibition of de novo purine synthesis by methotrexate (MTX) in human MCF-7 breast cancer cells." | 3.67 | Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. ( Allegra, CJ; Baram, J; Drake, JC; Hoang, K; Yeh, GC, 1987) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| " Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer." | 3.67 | [Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987) |
| " In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs." | 3.67 | [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987) |
| " Therapeutic safety was evaluated by analyses of adverse events with the recommended dose." | 2.72 | [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. ( Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006) |
| "Patients with relapsed, advanced breast cancer with evaluable lesions were given 5'-DFUR at 800 mg/day/body and CPA at 100 mg/day/body for 2 weeks, then underwent 2 weeks of drug withdrawal." | 2.72 | Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer. ( Ando, Y; Hara, Y; Itoh, K; Itoh, Y; Iwase, H; Iwata, H; Karamatsu, S; Kobayashi, S; Kuzushima, T; Sugiura, H; Toyama, T; Yamashita, H; Yamashita, T, 2006) |
| "In all, 101 patients with metastatic breast cancer were enrolled in the study, and the data for 94 eligible patients of these were evaluated." | 2.71 | The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. ( Goto, T; Kasumi, F; Kutomi, G; Makita, M; Nishimura, S; Tada, K; Tanabe, M; Tokudome, N; Yoshimoto, M, 2003) |
| " The purpose of the present study was to examine the efficacy of long-term administration of 5'-DFUR/CPA for patients with recurrent breast cancer." | 2.71 | The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. ( Aihara, N; Fukunaga, M; Iba, T; Kidokoro, A; Suda, M; Sugiyama, K, 2004) |
| "Capecitabine is a three-step prodrug that was rationally designed to be a more effective and safer alternative to its intermediate metabolite, 5'-deoxy-5-fluorouridine (5'-DFUR)." | 2.71 | Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ( Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N, 2005) |
| " The mean dosage per course of TXT was 58." | 2.71 | [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)]. ( Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005) |
| "In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life." | 2.70 | 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001) |
| "We enrolled 1217 primary breast cancer patients and randomly assigned them into two treatment groups; one received six-month postoperative 5'-DFUR treatment by consecutive or intermittent administration, and the other surgery alone." | 2.70 | The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. ( Abe, O; Abe, R; Asaishi, K; Enomoto, K; Hattori, T; Hayasaka, H; Hirata, K; Izuo, M; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Nakazato, H; Nomura, Y; Ohashi, Y; Ota, J; Senoo, T; Sonoo, H; Sugimachi, K; Taguchi, T; Toge, T; Toi, M; Tominaga, T; Uchino, J; Watanabe, H; Yamaguchi, S; Yoshida, M, 2002) |
| "Chemotherapeutic management of breast cancers is a difficult task as they show significant differences in chemosensitivity." | 2.69 | Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. ( Kazui, T; Kimura, T; Kobayashi, T; Sugimura, H; Suzuki, K; Uno, T; Yoshida, M; Yoshida, T, 1999) |
| "Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin." | 2.67 | Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994) |
| "5'-DFUR is a promising drug for breast cancer treatment, and its tablet form makes chemotherapy easier for the patient." | 2.67 | [Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions]. ( Inaji, H; Miura, S; Morimoto, K; Ohta, J; Taguchi, T; Ueda, N; Yayoi, K, 1992) |
| "5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day." | 2.66 | [Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. ( Imamura, Y; Irie, K; Nakamura, T; Suehiro, I; Yasutake, K; Yoshida, M; Yoshimura, Y, 1985) |
| "A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases." | 2.65 | Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. ( Colsky, J; Cummings, FJ; Gelman, R; Israel, L; Kuperminc, M; Skeel, RT; Tormey, D, 1981) |
| "A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out." | 2.38 | [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992) |
| "We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy." | 1.35 | [Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "Two patients were diagnosed as advanced breast cancer with multiple bone metastases." | 1.33 | [Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005) |
| " The significance of treatment dosage and duration was obvious when 5-DFUR and Tam cotreatment was observed to be antagonistic in 3-day cultures of a second MCF-7 subline and T47D cells." | 1.33 | Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells. ( Bollig, A; Du, QQ; Fan, ST; Liao, J; Sarkar, FH; Yu, B, 2005) |
| "Capecitabine is a new oral fluoropyrimidine derivative." | 1.33 | [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)]. ( Ebi, H; Minami, H, 2005) |
| "ErbB2 overexpressing breast tumors have a poor prognosis and a high risk to develop chemoresistance to therapeutic treatment." | 1.33 | 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. ( Bader, Y; Bernhaus, A; Fritzer-Szekeres, M; Gueorguieva, M; Krupitza, G; Leisser, C; Mader, RM; Madlener, S; Maier, S; Richter, S; Saiko, P; Schott, H; Strasser, S; Szekeres, T; Wesierska-Gadek, J, 2006) |
| "With a diagnosis of advanced breast cancer with skin invasion, she underwent right mastectomy with a free skin graft." | 1.32 | Massive mucinous carcinoma of the breast untreated for 6 years. ( Sakaguchi, K; Tsuchie, K; Yoneyama, F, 2003) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 1.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "We report a case of breast cancer with spinal and vertebral lesions." | 1.32 | [Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases]. ( Hashiguchi, H; Hirooka, Y; Kamasako, A; Nozaka, K; Ohgami, Y; Otani, S; Takebayashi, M; Tanida, O; Toyota, N; Wakatsuki, T, 2004) |
| " Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery." | 1.31 | [One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful]. ( Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002) |
| "She was diagnosed as having advanced breast cancer of stage T4N3 (supraclavicular lymph node) M1 (bone)." | 1.31 | [Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. ( Fujii, T; Hanaoka, T; Ishida, K; Kawashima, K; Mihara, Y; Takahashi, T, 2000) |
| "She was diagnosed with stage IV breast cancer." | 1.31 | [Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer]. ( Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K, 2001) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 1.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| " Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day." | 1.31 | [A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA]. ( Otsuka, T; Tashiro, S; Terashima, Y, 2002) |
| "Mitoxantrone (MIT) is a new anthraquinone anticancer agent." | 1.30 | [Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998) |
| "Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study." | 1.30 | [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999) |
| "Brain metastases were also found." | 1.30 | [A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K, 1999) |
| "Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies." | 1.30 | [Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999) |
| "The human MCF-7 breast cancer cell line was transfected with the dThdPase cDNA and expressed a 45 kDa protein that was detected with anti-dThdPase antibody." | 1.29 | Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. ( Bicknell, R; Harris, AL; Moghaddam, A; Patterson, AV; Stratford, IJ; Talbot, DC; Zhang, H, 1995) |
| "Mitoxantrone (MIT) is a new anthraquinone anti-cancer agent." | 1.29 | [Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer]. ( Hirayama, R; Ichikawa, W; Mishima, Y; Miyanaga, T; Nihei, Z; Sawai, S; Shoji, Y; Yamashita, T; Yoshinaga, K, 1993) |
| "A 58-year-old woman with multiple organ metastases from breast cancer who had undergone radical mastectomy three years ago, was treated with oral 5'-DFUR 600 mg/day." | 1.29 | [A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective]. ( Dohi, K; Gotoh, T; Kataoka, T; Nishiki, M; Okamoto, T; Sadamoto, S, 1993) |
| " In terms of ER stratification, ER(-) patients in the dosing groups showed increasing tendencies in S-phase and significant differences of G1- as well as G2+M phases." | 1.29 | [Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]. ( Fujii, A; Hamano, K; Kamio, T; Katoh, T; Kimura, T; Muraki, H; Yamamoto, K, 1993) |
| "A 55-year-old woman with recurrent breast cancer treated with sequential mastectomies, chemo-and hormonal therapy of UFT, CPM and TAM, achieved remission." | 1.29 | [A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA]. ( Kimura, M; Koida, T; Sekihara, M, 1996) |
| "We experienced 522 patients with breast carcinoma and 14 cases (2." | 1.29 | [A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy]. ( Matsumine, T; Matsumoto, J; Minami, T; Takami, M; Takanishi, K, 1996) |
| "In contrast, estrogen-independent human breast cancer cells do not activate this programmed cell death pathway following estrogen ablation." | 1.28 | Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. ( Armstrong, DK; Davidson, NE; Isaacs, JT; Ottaviano, YL, 1992) |
| "In case of breast cancer, it was 10 times higher than normal tissue." | 1.28 | [A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon]. ( Adachi, I; Douden, K; Hayashi, H; Hikishima, H; Iwa, T; Munemoto, Y; Okada, Y; Omura, K; Watanabe, Y, 1990) |
| " With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor." | 1.27 | 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. ( Armstrong, RD; Cadman, E, 1983) |
| " The optimal daily dosage was considered to be 800-1,200 mg/body/day." | 1.27 | [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985) |
| "1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug." | 1.27 | [Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985) |
| "Minimal breast cancer was present in eight out of nine cases." | 1.27 | [Diagnosis of minimal breast cancer by diagnostic hormonal treatment]. ( Iwasa, Z; Matsunami, N; Saeki, Y; Yasutomi, M, 1986) |
| " Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index." | 1.27 | Phase II clinical evaluation of doxifluridine. ( Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986) |
| " This diarrhea, however, disappeared rapidly by decreasing the dosage or termination of treatment." | 1.27 | [A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Tsukagoshi, S, 1987) |
| "5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks." | 1.27 | [Clinical trial of 5'-DFUR in patients with recurrent breast cancer]. ( Komaki, K; Konishi, Y; Miki, H; Monden, Y; Morimoto, T; Ooshimo, K; Tanaka, T; Uomine, Y; Yamakawa, T, 1988) |
| " 5'-DFUR was administered three or four times a day at a daily dosage of 600 to 1200 mg." | 1.27 | [Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group]. ( Gocho, Y; Ishitani, K; Kogo, Y; Kouda, K; Koyama, R; Matsuda, M; Nagai, T; Niitsu, Y; Saijo, N; Urushizaki, I, 1985) |
| "Above all, some CR cases in breast cancer indicated remarkable superiority of this drug for monotherapy." | 1.27 | [Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Fujita, M; Nakano, Y; Ohota, J; Taguchi, T, 1985) |
| "Samples from 11 patients with breast cancer treated with 5-FU-containing chemotherapy regimens were assayed." | 1.26 | The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man. ( Ardalan, B; Cooney, D; Lippman, M; Macdonald, J; Schein, P, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (26.77) | 18.7374 |
| 1990's | 66 (33.33) | 18.2507 |
| 2000's | 73 (36.87) | 29.6817 |
| 2010's | 4 (2.02) | 24.3611 |
| 2020's | 2 (1.01) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 2 |
| Han, M | 2 |
| Zhang, F | 2 |
| Yang, X | 1 |
| Du, J | 2 |
| Zhang, H | 3 |
| Li, W | 2 |
| Chen, S | 1 |
| Wang, X | 1 |
| Derissen, EJB | 1 |
| Huitema, ADR | 1 |
| Rosing, H | 1 |
| Schellens, JHM | 1 |
| Beijnen, JH | 1 |
| Nishimura, R | 2 |
| Tominaga, T | 12 |
| Kimura, M | 3 |
| Yanagita, Y | 1 |
| Tamaki, N | 1 |
| Asaishi, K | 3 |
| Okamoto, Y | 2 |
| Okuyama, N | 2 |
| Takeuchi, H | 1 |
| Inaba, M | 1 |
| Doi, T | 1 |
| Sakurai, T | 3 |
| Umemura, T | 2 |
| Jinta, E | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 2 |
| Shimizu, S | 2 |
| Nakayama, T | 1 |
| Noguchi, S | 3 |
| Saito, Y | 1 |
| Suzuki, Y | 2 |
| Tokuda, Y | 1 |
| Ait-Tihyaty, M | 1 |
| Rachid, Z | 1 |
| Mihalcioiu, C | 1 |
| Jean-Claude, BJ | 1 |
| Kusama, M | 5 |
| Hiraoka, M | 1 |
| Koyama, H | 5 |
| Inoue, T | 1 |
| Kono, N | 1 |
| Kono, M | 1 |
| Kodama, H | 1 |
| Inaji, H | 3 |
| Sako, M | 1 |
| Suzuki, R | 1 |
| Harada, T | 1 |
| Hara, A | 1 |
| Tsunematsu, I | 1 |
| Matsubara, C | 1 |
| Izumi, N | 1 |
| Iwamoto, S | 1 |
| Satake, K | 1 |
| Wang, Z | 1 |
| Wang, S | 1 |
| Zhu, F | 1 |
| Ye, Y | 1 |
| Yu, Y | 1 |
| Qiao, X | 1 |
| Mader, RM | 3 |
| Schrolnberger, C | 1 |
| Rizovski, B | 1 |
| Brunner, M | 1 |
| Wenzel, C | 1 |
| Locker, G | 1 |
| Eichler, HG | 1 |
| Mueller, M | 1 |
| Steger, GG | 1 |
| Sawada, M | 1 |
| Ono, Y | 2 |
| Fukushima, M | 3 |
| Kim, R | 1 |
| Murakami, S | 2 |
| Toge, T | 4 |
| Miura, S | 4 |
| Sugimachi, K | 2 |
| Yamaguchi, S | 2 |
| Hirata, K | 2 |
| Monden, Y | 3 |
| Nomura, Y | 3 |
| Toi, M | 5 |
| Kimijima, I | 2 |
| Sonoo, H | 6 |
| Ikeda, T | 1 |
| Morimoto, T | 5 |
| Ota, J | 3 |
| Ohashi, Y | 3 |
| Abe, O | 6 |
| Zimmermann, A | 1 |
| Walt, H | 1 |
| Haller, U | 1 |
| Baas, P | 1 |
| Klein, SD | 1 |
| Yoneyama, F | 1 |
| Tsuchie, K | 1 |
| Sakaguchi, K | 1 |
| Sawada, T | 2 |
| Kou, Y | 1 |
| Xu, BH | 1 |
| Zhang, YJ | 1 |
| Zheng, X | 1 |
| Wu, Q | 1 |
| Wu, XT | 1 |
| DAO, TL | 1 |
| GRINBERG, R | 1 |
| HEIDELBERGER, C | 1 |
| ANSFIELD, FJ | 4 |
| CURRERI, AR | 1 |
| SULLIVAN, RD | 2 |
| ZUREK, WZ | 1 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| Akao, S | 3 |
| Inoue, K | 4 |
| Yoshimoto, M | 2 |
| Tada, K | 1 |
| Tokudome, N | 1 |
| Kutomi, G | 1 |
| Tanabe, M | 1 |
| Goto, T | 2 |
| Nishimura, S | 2 |
| Makita, M | 1 |
| Kasumi, F | 1 |
| Tokunaga, Y | 1 |
| Hosogi, H | 1 |
| Nakagami, M | 1 |
| Tokuka, A | 1 |
| Ohsumi, K | 1 |
| Tomono, H | 1 |
| Kitamura, H | 1 |
| Iwase, M | 1 |
| Kuze, S | 1 |
| Ohi, S | 1 |
| Itoh, Y | 2 |
| Nakazawa, H | 1 |
| Fujita, H | 1 |
| Oya, J | 1 |
| Suzuki, O | 1 |
| Sekishita, Y | 1 |
| Shiono, T | 1 |
| Kondo, S | 1 |
| Kato, H | 1 |
| Ishii, K | 1 |
| Tsugawa, K | 1 |
| Nakamura, M | 2 |
| Ohnishi, I | 1 |
| Miwa, K | 1 |
| Pegram, MD | 1 |
| Konecny, GE | 1 |
| O'Callaghan, C | 1 |
| Beryt, M | 1 |
| Pietras, R | 1 |
| Slamon, DJ | 1 |
| Yamada, T | 1 |
| Yuyama, Y | 1 |
| Okazaki, Y | 1 |
| Miyoshi, K | 1 |
| Ohtsuka, S | 1 |
| Inagaki, M | 1 |
| Ohsaki, T | 1 |
| Fuchimoto, S | 1 |
| Yumura, M | 1 |
| Nakagawa, T | 1 |
| Iba, T | 2 |
| Kidokoro, A | 2 |
| Fukunaga, M | 2 |
| Sugiyama, K | 2 |
| Aihara, N | 2 |
| Suda, M | 2 |
| Otani, S | 1 |
| Toyota, N | 1 |
| Nozaka, K | 1 |
| Wakatsuki, T | 1 |
| Takebayashi, M | 1 |
| Kamasako, A | 1 |
| Tanida, O | 1 |
| Hashiguchi, H | 1 |
| Ohgami, Y | 1 |
| Hirooka, Y | 1 |
| Tagaya, N | 2 |
| Kakihara, Y | 2 |
| Hamada, K | 2 |
| Kubota, K | 3 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 2 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Suda, T | 1 |
| Ebi, H | 2 |
| Sigeoka, Y | 1 |
| Saeki, T | 1 |
| Kawada, K | 1 |
| Igarashi, T | 1 |
| Usubuchi, N | 1 |
| Ueda, R | 1 |
| Sasaki, Y | 1 |
| Minami, H | 2 |
| Sakamoto, E | 1 |
| Hasegawa, H | 1 |
| Komatsu, S | 1 |
| Hiromatsu, T | 1 |
| Itazu, K | 1 |
| Tabata, T | 1 |
| Kawai, K | 1 |
| Fukami, Y | 1 |
| Fujino, S | 1 |
| Kan, N | 1 |
| Lee, CJ | 1 |
| Inamoto, T | 1 |
| Mise, K | 1 |
| Sawai, S | 2 |
| Okamoto, M | 1 |
| Hori, T | 1 |
| Maruhashi, K | 1 |
| Yamauchi, A | 2 |
| Fujii, K | 1 |
| Mitsumori, M | 1 |
| Higashide, S | 1 |
| Takemoto, Y | 1 |
| Okamura, T | 1 |
| Kihara, M | 2 |
| Kontani, K | 1 |
| Yokomise, H | 1 |
| Bollig, A | 1 |
| Du, QQ | 1 |
| Fan, ST | 1 |
| Yu, B | 1 |
| Sarkar, FH | 1 |
| Liao, J | 1 |
| Nakagawa, A | 1 |
| Mori, S | 1 |
| Tachibana, M | 1 |
| Suzuki, N | 1 |
| Maier, S | 2 |
| Strasser, S | 2 |
| Saiko, P | 2 |
| Leisser, C | 2 |
| Sasgary, S | 1 |
| Grusch, M | 1 |
| Madlener, S | 2 |
| Bader, Y | 2 |
| Hartmann, J | 1 |
| Schott, H | 2 |
| Szekeres, T | 2 |
| Fritzer-Szekeres, M | 2 |
| Krupitza, G | 2 |
| Yan, R | 1 |
| Wan, L | 1 |
| Pizzorno, G | 1 |
| Cao, D | 1 |
| Ikeda, M | 1 |
| Tanaka, K | 3 |
| Kurebayashi, J | 3 |
| Tangoku, A | 1 |
| Komaki, K | 2 |
| Kataoka, T | 2 |
| Ishiguro, K | 1 |
| Yoshizawa, K | 1 |
| Molina-Arcas, M | 1 |
| Moreno-Bueno, G | 1 |
| Cano-Soldado, P | 1 |
| Hernández-Vargas, H | 1 |
| Casado, FJ | 1 |
| Palacios, J | 1 |
| Pastor-Anglada, M | 1 |
| Yamashita, T | 3 |
| Yamashita, H | 1 |
| Karamatsu, S | 1 |
| Itoh, K | 1 |
| Hara, Y | 2 |
| Ando, Y | 1 |
| Sugiura, H | 1 |
| Kuzushima, T | 1 |
| Toyama, T | 2 |
| Iwata, H | 2 |
| Kobayashi, S | 1 |
| Iwase, H | 2 |
| Bernhaus, A | 1 |
| Gueorguieva, M | 1 |
| Richter, S | 1 |
| Wesierska-Gadek, J | 1 |
| Yamamoto, Y | 2 |
| Cummings, FJ | 2 |
| Gelman, R | 1 |
| Skeel, RT | 1 |
| Kuperminc, M | 1 |
| Israel, L | 1 |
| Colsky, J | 1 |
| Tormey, D | 1 |
| Major, PP | 1 |
| Egan, E | 1 |
| Herrick, D | 2 |
| Kufe, DW | 2 |
| Ardalan, B | 1 |
| Macdonald, J | 1 |
| Cooney, D | 1 |
| Lippman, M | 1 |
| Schein, P | 1 |
| Armstrong, RD | 2 |
| Cadman, E | 2 |
| Gesmonde, J | 1 |
| Wu, T | 1 |
| Gunner, L | 1 |
| Fujita, F | 4 |
| Fujita, M | 5 |
| Taguchi, T | 11 |
| Donehower, RC | 1 |
| Allegra, JC | 1 |
| Lippman, ME | 1 |
| Chabner, BA | 2 |
| Barberi-Heyob, M | 1 |
| Weber, B | 1 |
| Merlin, JL | 1 |
| Dittrich, C | 1 |
| de Bruijn, EA | 1 |
| Luporsi, E | 1 |
| Guillemin, F | 1 |
| Patterson, AV | 1 |
| Moghaddam, A | 1 |
| Bicknell, R | 1 |
| Talbot, DC | 1 |
| Stratford, IJ | 1 |
| Harris, AL | 1 |
| Taniguchi, T | 1 |
| Hayashi, K | 2 |
| Kobayashi, J | 1 |
| Ishikawa, H | 3 |
| Asaumi, S | 1 |
| Iwanami, K | 1 |
| Matsumoto, H | 1 |
| Kawashima, K | 2 |
| Yokoe, T | 2 |
| Iino, Y | 3 |
| Morishita, Y | 3 |
| Senga, O | 1 |
| Miyakawa, M | 1 |
| Hikita, H | 1 |
| Horigome, N | 1 |
| Kouzu, S | 1 |
| Kuwae, K | 1 |
| Hanaoka, T | 3 |
| Yoshida, K | 1 |
| Raschko, JW | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Newman, E | 1 |
| Somlo, G | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Tohma, H | 1 |
| Noshiro, H | 1 |
| Hachiya, Y | 1 |
| Akashi, Y | 1 |
| Miyoshi, A | 1 |
| Koyanagi, Y | 4 |
| Sekine, M | 1 |
| Serizawa, H | 1 |
| Ebihara, Y | 1 |
| Hirota, T | 1 |
| Nakamura, Y | 3 |
| Matsunaga, T | 2 |
| Yamamoto, T | 1 |
| Funatsuka, M | 1 |
| Naitoh, A | 1 |
| Yano, S | 1 |
| Tamura, K | 1 |
| Alberto, P | 2 |
| Takeshita, T | 1 |
| Masuyama, H | 1 |
| Tanahasi, T | 1 |
| Suzuki, H | 1 |
| Ichikawa, W | 2 |
| Nihei, Z | 2 |
| Shoji, Y | 1 |
| Miyanaga, T | 2 |
| Yoshinaga, K | 1 |
| Hirayama, R | 1 |
| Mishima, Y | 1 |
| Okamoto, T | 1 |
| Gotoh, T | 1 |
| Sadamoto, S | 1 |
| Nishiki, M | 2 |
| Dohi, K | 1 |
| Kimura, T | 3 |
| Muraki, H | 1 |
| Kamio, T | 1 |
| Katoh, T | 2 |
| Fujii, A | 1 |
| Yamamoto, K | 2 |
| Hamano, K | 1 |
| Kurihara, T | 1 |
| Higashi, Y | 2 |
| Suemasu, K | 2 |
| Kanoh, T | 1 |
| Tabei, T | 3 |
| Enomoto, K | 2 |
| Abe, R | 2 |
| Nakazato, H | 2 |
| Koida, T | 1 |
| Sekihara, M | 1 |
| Masuda, N | 1 |
| Yayoi, E | 4 |
| Furukawa, J | 1 |
| Maruhashi, S | 1 |
| Tokunaga, M | 1 |
| Takiguchi, S | 1 |
| Matsui, S | 1 |
| Yano, H | 1 |
| Tateishi, H | 1 |
| Kinuta, M | 1 |
| Maruyama, H | 1 |
| Ooi, H | 1 |
| Okamura, J | 1 |
| Matsumoto, J | 1 |
| Minami, T | 1 |
| Takami, M | 1 |
| Takanishi, K | 1 |
| Matsumine, T | 1 |
| Yoshida, M | 4 |
| Abe, S | 1 |
| Kojima, M | 1 |
| Soma, R | 1 |
| Wagner, CR | 1 |
| Ballato, G | 1 |
| Akanni, AO | 1 |
| McIntee, EJ | 1 |
| Larson, RS | 1 |
| Chang, S | 1 |
| Abul-Hajj, YJ | 1 |
| Nishibe, M | 1 |
| Kuribayashi, H | 1 |
| Sato, T | 1 |
| Watanabe, I | 1 |
| Nishihara, H | 1 |
| Endo, M | 1 |
| Fujimoto-Ouchi, K | 2 |
| Matsumoto, T | 1 |
| Tanaka, Y | 2 |
| Ishitsuka, H | 1 |
| Yamada, Y | 2 |
| Miyagawa, T | 1 |
| Toyoda, H | 1 |
| Uesato, K | 1 |
| Asanuma, F | 1 |
| Katsumata, K | 1 |
| Shibata, K | 1 |
| Murano, A | 1 |
| Kawasaki, M | 1 |
| Moriwaki, R | 1 |
| Nagakawa, Y | 1 |
| Ogata, T | 1 |
| Avril, N | 1 |
| Dose, J | 1 |
| Ziegler, S | 1 |
| Jänicke, F | 1 |
| Schwaiger, M | 1 |
| Sugamata, N | 1 |
| Maemura, M | 1 |
| Takei, H | 1 |
| Horiguchi, J | 1 |
| Takeyoshi, I | 1 |
| Ohwada, S | 1 |
| Kusaba, T | 1 |
| Ishida, T | 1 |
| Yokomori, T | 1 |
| Fujii, T | 2 |
| Endo, K | 1 |
| Shiozaki, H | 1 |
| Aiba, S | 1 |
| Takano, A | 1 |
| Kishi, S | 1 |
| Takatsuka, Y | 4 |
| Shin, E | 1 |
| Osanai, T | 1 |
| Shimizu, C | 1 |
| Uetake, H | 1 |
| Iida, S | 1 |
| Nishi, N | 1 |
| Togo, S | 1 |
| Sugihara, K | 1 |
| Bajetta, E | 1 |
| Biganzoli, L | 1 |
| Carnaghi, C | 1 |
| Di Bartolomeo, M | 1 |
| Spagnoli, I | 1 |
| Cassata, A | 1 |
| Galante, E | 1 |
| Mariani, L | 1 |
| Stampino, CG | 1 |
| Buzzoni, R | 1 |
| Yamane, E | 1 |
| Nanri, M | 1 |
| Chimori, Y | 1 |
| Oguro, A | 1 |
| Fujita, Y | 1 |
| Ikoma, H | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 2 |
| Maeda, N | 1 |
| Iwatsuki, K | 1 |
| Tsuzuki, T | 1 |
| Hirayama, A | 1 |
| Yamamoto, H | 2 |
| Ikenaka, K | 1 |
| Matsusaka, K | 1 |
| Miyauchi, A | 1 |
| Maeda, M | 1 |
| Fujitake, S | 2 |
| Maeda, Y | 3 |
| Shimizu, M | 2 |
| Nozaki, H | 2 |
| Tohyama, M | 2 |
| Kataoka, S | 2 |
| Sumimura, J | 1 |
| Morimoto, Y | 1 |
| Miyazaki, M | 1 |
| Ishikawa, S | 1 |
| Nagai, I | 1 |
| Kurosumi, M | 2 |
| Kottke, TJ | 1 |
| Blajeski, AL | 1 |
| Martins, LM | 1 |
| Mesner, PW | 1 |
| Davidson, NE | 2 |
| Earnshaw, WC | 1 |
| Armstrong, DK | 2 |
| Kaufmann, SH | 1 |
| Senoo, T | 2 |
| Takashima, S | 1 |
| Hoshino, K | 1 |
| Ikeda, H | 1 |
| Koyama, T | 1 |
| Tadaoka, N | 1 |
| Mizutani, H | 1 |
| Kuroda, T | 1 |
| Takahashi, N | 1 |
| Tashiro, H | 1 |
| Takahashi, I | 2 |
| Yamamura, S | 1 |
| Ishikawa, T | 1 |
| Yanaga, K | 1 |
| Wakasugi, K | 1 |
| Matsusaka, T | 1 |
| Kume, K | 1 |
| Suzuki, K | 1 |
| Kazui, T | 1 |
| Uno, T | 1 |
| Kobayashi, T | 1 |
| Yoshida, T | 1 |
| Sugimura, H | 1 |
| Kokufu, I | 2 |
| Taniguchi, H | 2 |
| Kim, YH | 2 |
| Fukuda, K | 2 |
| Yamamoto, M | 4 |
| Yano, T | 2 |
| Yamada, K | 2 |
| Kitano, H | 2 |
| Kaise, H | 2 |
| Nakayama, S | 2 |
| Yoneda, K | 1 |
| Aoki, T | 2 |
| Yamamoto, S | 2 |
| Kunisue, H | 2 |
| Udagawa, K | 1 |
| Arime, I | 1 |
| Shimozuma, K | 4 |
| Tanaka, R | 1 |
| Fukushima, H | 1 |
| Sato, K | 1 |
| Matsuda, M | 2 |
| Goya, T | 1 |
| Yasui, M | 1 |
| Nishi, T | 1 |
| Yamasaki, M | 1 |
| Kishibuchi, M | 1 |
| Yagyu, T | 1 |
| Kawasaki, K | 2 |
| Kiyono, T | 1 |
| Nishiwaki, M | 1 |
| Okuda, K | 1 |
| Tsujitsuka, K | 1 |
| Kano, Y | 1 |
| Koga, T | 1 |
| Ishimaru, K | 1 |
| Sumiyama, M | 1 |
| Harada, Y | 1 |
| Ohuchi, N | 1 |
| Ohnuki, K | 1 |
| Amano, G | 1 |
| Yoshida, R | 1 |
| Furuta, A | 1 |
| Ikegaki, H | 1 |
| Kijima, G | 1 |
| Satomi, S | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Igarashi, K | 1 |
| Kikuchi, M | 1 |
| Oura, S | 1 |
| Tamaki, T | 1 |
| Kokawa, Y | 1 |
| Naito, Y | 1 |
| Ishida, K | 1 |
| Takahashi, T | 1 |
| Mihara, Y | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Takahashi, H | 3 |
| Todo, S | 2 |
| Hata, Y | 1 |
| Sasaki, F | 2 |
| Ogita, M | 1 |
| Uchino, J | 2 |
| Akasaka, Y | 1 |
| Nakanishi, Y | 1 |
| Sawada, Y | 1 |
| Mizutani, M | 1 |
| Iwase, T | 1 |
| Murai, H | 1 |
| Watanabe, K | 1 |
| Taguchi, K | 1 |
| Watanabe, Y | 2 |
| Kaiga, T | 1 |
| Ueda, T | 1 |
| Fujii, M | 1 |
| Maruyama, S | 1 |
| Okumoto, T | 1 |
| Ino, H | 1 |
| Kanaya, Y | 1 |
| Otani, J | 1 |
| Yokoyama, N | 1 |
| Soda, M | 1 |
| Sato , K | 1 |
| Hiraide, H | 1 |
| Tamakuma, S | 1 |
| Maruyama, M | 1 |
| Touma, M | 1 |
| Okamura, H | 1 |
| Matsumoto, F | 1 |
| Yagi, Y | 1 |
| Mochizuki, H | 1 |
| Fukuda, Y | 1 |
| Hirao, S | 1 |
| Koyama, I | 1 |
| Takatori, H | 1 |
| Terakura, M | 1 |
| Mayumi, K | 1 |
| Tsukazaki, Y | 1 |
| Kinoshita, H | 1 |
| De Larco, JE | 1 |
| Wuertz, BR | 1 |
| Manivel, JC | 1 |
| Furcht, LT | 1 |
| Aoyama, H | 1 |
| Mitsuyama, S | 1 |
| Asaga, T | 1 |
| Nakagomi, H | 1 |
| Miyauchi, Y | 1 |
| Okuda, J | 1 |
| Muto, S | 1 |
| Akaike, H | 1 |
| Takahashi, M | 1 |
| Mitui, T | 1 |
| Ashizawa, I | 1 |
| Chiba, S | 1 |
| Nakazawa, M | 1 |
| Imamura, K | 1 |
| Otsuki, T | 1 |
| Chino, Y | 1 |
| Ubukata, N | 1 |
| Yoshihara, K | 1 |
| Tani, T | 1 |
| Ogata, M | 1 |
| Mackey, JR | 1 |
| Jennings, LL | 1 |
| Clarke, ML | 1 |
| Santos, CL | 1 |
| Dabbagh, L | 1 |
| Vsianska, M | 1 |
| Koski, SL | 1 |
| Coupland, RW | 1 |
| Baldwin, SA | 1 |
| Young, JD | 1 |
| Cass, CE | 1 |
| Kitahara, S | 1 |
| Ogata, H | 1 |
| Katagiri, T | 1 |
| Nonaka, K | 1 |
| Shiba, T | 1 |
| Nukatsuka, M | 2 |
| Fujioka, A | 2 |
| Nakagawa, F | 2 |
| Ohshimo, H | 2 |
| Hayasaka, H | 1 |
| Izuo, M | 1 |
| Watanabe, H | 1 |
| Hattori, T | 1 |
| Otsuka, T | 1 |
| Terashima, Y | 1 |
| Tashiro, S | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Miyamoto, H | 1 |
| Yoshida, S | 1 |
| Imatomi, M | 1 |
| Saitoh, T | 1 |
| Nakata, A | 1 |
| Ota, D | 1 |
| Misaka, T | 1 |
| Matunaga, T | 1 |
| Kitazato, K | 1 |
| Meyer, JS | 1 |
| Facher, R | 1 |
| Schabel, FM | 1 |
| Hoovis, ML | 1 |
| Calabresi, P | 2 |
| Morimoto, K | 1 |
| Ohta, J | 1 |
| Ueda, N | 1 |
| Yayoi, K | 1 |
| Koh, J | 1 |
| Murayama, Y | 1 |
| Sano, M | 1 |
| Katai, H | 1 |
| Maeda, K | 1 |
| Sakai, S | 1 |
| Yamamoto, O | 1 |
| Hashimoto, M | 1 |
| Hosoda, Y | 1 |
| Sakai, K | 2 |
| Irie, K | 3 |
| Terasawa, T | 3 |
| Shimoyama, T | 1 |
| Kawahara, T | 3 |
| Okumura, T | 2 |
| Yasutake, K | 2 |
| Tsumura, I | 1 |
| Kobayakawa, K | 1 |
| Miyauchi, K | 3 |
| Aikawa, T | 2 |
| Maeura, Y | 2 |
| Hirai, T | 2 |
| Kotsuma, Y | 2 |
| Isaacs, JT | 1 |
| Ottaviano, YL | 1 |
| Tamm, I | 1 |
| Cardinale, I | 1 |
| Sehgal, PB | 1 |
| Yoshinaka, K | 1 |
| Yagi, M | 1 |
| Ohtagaki, S | 1 |
| Hrushesky, WJ | 1 |
| Maeda, H | 1 |
| Miyamoto, T | 1 |
| Mochinaga, N | 1 |
| Tsunoda, T | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Nishizawa, Y | 1 |
| Imaoka, S | 1 |
| Iwanaga, T | 1 |
| Kaji, M | 1 |
| Kitada, M | 1 |
| Satomi, T | 2 |
| Arai, Y | 1 |
| Endo, T | 1 |
| Miyake, Y | 1 |
| Kido, C | 1 |
| Munemoto, Y | 1 |
| Omura, K | 1 |
| Hikishima, H | 1 |
| Okada, Y | 1 |
| Hayashi, H | 1 |
| Adachi, I | 1 |
| Douden, K | 1 |
| Iwa, T | 1 |
| Allegra, CJ | 2 |
| Drake, JC | 2 |
| Lutz, R | 1 |
| Rodbard, D | 1 |
| Jolivet, J | 1 |
| Kaysen, J | 1 |
| Spriggs, D | 1 |
| Kufe, D | 1 |
| Hoang, K | 1 |
| Yeh, GC | 1 |
| Baram, J | 1 |
| Kosaka, A | 1 |
| Sumiyoshi, K | 1 |
| Ando, J | 1 |
| Berry, JP | 1 |
| Lespinats, G | 1 |
| Escaig, F | 1 |
| Boumati, P | 1 |
| Tlouzeau, S | 1 |
| Cavellier, JF | 1 |
| Galle, P | 1 |
| Enomoto, T | 1 |
| Watanabe, A | 1 |
| Yoshida, Y | 2 |
| Ogawa, N | 1 |
| Niitani, H | 1 |
| Kimura, K | 1 |
| Saito, T | 1 |
| Nakao, I | 1 |
| Urushizaki, I | 2 |
| Ohta, K | 1 |
| Kurihara, M | 1 |
| Kitamura, M | 1 |
| Kosaki, G | 1 |
| Okajima, K | 1 |
| Tomita, K | 1 |
| Yamaguchi, A | 2 |
| Imamura, Y | 1 |
| Yoshimura, Y | 1 |
| Nakamura, T | 1 |
| Suehiro, I | 1 |
| Hoshino, A | 2 |
| Ohara, K | 1 |
| Kamiya, O | 2 |
| Nagata, K | 1 |
| Kawakubo, A | 1 |
| Ozaki, Y | 1 |
| Suzuki, A | 1 |
| Ogasawara, T | 1 |
| Sugiura, I | 1 |
| Iwasa, Z | 1 |
| Saeki, Y | 1 |
| Matsunami, N | 1 |
| Yasutomi, M | 1 |
| Hurteloup, P | 1 |
| Armand, JP | 1 |
| Cappelaere, P | 1 |
| Metz, R | 1 |
| Kerbrat, P | 1 |
| Keiling, R | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Schraub, S | 1 |
| Bastit, P | 1 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Yasue, M | 1 |
| Kinoshita, T | 1 |
| Hiraiwa, K | 1 |
| Hachisuka, K | 1 |
| Sakamoto, Y | 2 |
| Inaba, H | 2 |
| Yamauchi, T | 1 |
| Pagana, TJ | 1 |
| Somers, WR | 1 |
| Tsukagoshi, S | 1 |
| Jungi, WF | 1 |
| Siegenthaler, P | 1 |
| Mermillod, B | 1 |
| Obrecht, JP | 1 |
| Decoster, G | 1 |
| Cavalli, F | 1 |
| Yamakawa, T | 1 |
| Konishi, Y | 1 |
| Uomine, Y | 1 |
| Miki, H | 1 |
| Ooshimo, K | 1 |
| Kogo, Y | 1 |
| Kouda, K | 1 |
| Ishitani, K | 1 |
| Niitsu, Y | 1 |
| Gocho, Y | 1 |
| Koyama, R | 1 |
| Nagai, T | 1 |
| Saijo, N | 1 |
| Wells, JJ | 1 |
| Nostrant, TT | 1 |
| Wilson, JA | 1 |
| Gyves, JW | 1 |
| Fujimoto, S | 1 |
| Wang, Y | 1 |
| Ogawa, M | 1 |
| Nakano, Y | 1 |
| Ohota, J | 1 |
| Shingleton, WW | 1 |
| Sedransk, N | 1 |
| Johnson, RO | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Ramirez, G | 1 |
| DeConti, RC | 1 |
| Kaplan, SR | 2 |
| Papac, RJ | 1 |
| Oldham, RK | 1 |
| Siwarski, D | 1 |
| McCoy, JL | 1 |
| Plata, EJ | 1 |
| Herberman, RB | 1 |
| Miller, E | 1 |
| Morrow, LB | 1 |
| Burrow, GN | 1 |
| Mulrow, PJ | 1 |
11 reviews available for floxuridine and Breast Neoplasms
| Article | Year |
|---|---|
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me | 1963 |
Uridine phosphorylase in breast cancer: a new prognostic factor?
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycy | 2006 |
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia; | 1996 |
[Diagnosis of breast carcinoma and locoregional lymph nodes with positron emission tomography].
Topics: Blood Glucose; Breast Neoplasms; Female; Floxuridine; Humans; Lymph Nodes; Lymphatic Metastasis; Neo | 1997 |
[Treatment strategy for recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophospha | 1998 |
[Recent development of oral anti-cancer drugs for breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clin | 1999 |
[Thymidine phosphorylase as a prognostic factors of breast cancers].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free Survival; Female; Floxuridine; Human | 2000 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
[A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female; Flox | 1992 |
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F | 1991 |
37 trials available for floxuridine and Breast Neoplasms
| Article | Year |
|---|---|
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Topics: Activation, Metabolic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytidine Triphosphate; Dea | 2018 |
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2008 |
[Assessment of complications in a randomized controlled study on multimodality therapy for patients following breast-conserving surgery: Kansai Breast Cancer Radiotherapy Research Group (5'-KBR)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Ad | 2002 |
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2003 |
The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2003 |
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2004 |
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplas | 2005 |
[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marr | 2005 |
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Ne | 2006 |
Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2006 |
Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Cytarabine; Drug Evaluation; Drug Therapy, Combi | 1981 |
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1995 |
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1994 |
Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 1993 |
[A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan].
Topics: Adult; Alopecia; Anorexia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1996 |
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia; | 1996 |
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; M | 1997 |
A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1998 |
Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Proto | 1998 |
[Clinical application of FdUrd to meningeal dissemination of malignant tumors].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Drug Admin | 1998 |
[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1999 |
[Usefulness of low dose 5'-DFUR (5'-deoxy-5-fluorouridine) for advanced or recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Adm | 1999 |
[Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclop | 1999 |
Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Division; Drug | 1999 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin | 2001 |
[The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients].
Topics: Adult; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Adm | 2001 |
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free Survival; Female; Floxu | 2002 |
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free S | 2002 |
[Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Drug Administr | 1992 |
[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri | 1990 |
[Clinical trial of 5'-DFUR against various malignant tumors].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Adm | 1985 |
[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedul | 1985 |
[Clinical trial of a new fluorinated pyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Admin | 1986 |
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon | 1968 |
151 other studies available for floxuridine and Breast Neoplasms
| Article | Year |
|---|---|
Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; DNA; Drug Carriers; Drug Delivery Syste | 2020 |
Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; DNA; Doxorubicin; Drug Delivery Syste | 2020 |
[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Floxurid | 2008 |
Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2009 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferat | 2012 |
[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide(DMpC)combination therapy found effective for case of chest wall recurrent breast cancer with bone and pleural metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophospha | 2012 |
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2002 |
Expression of extracellular signal-regulated kinase and its relationship with clinicopathological characteristics of breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Humans; Mitogen-Activated Pr | 2002 |
Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine | 2002 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combine | 2003 |
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; DNA, Complementary; Dose-Response Rela | 2003 |
Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Basal Cell; Floxuridine; Fluorouracil; Humans; Male; Mesopor | 2003 |
Massive mucinous carcinoma of the breast untreated for 6 years.
Topics: Adenocarcinoma, Mucinous; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Floxurid | 2003 |
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2003 |
[Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
Fluorinated pyrimidines in treatment of breast cancer patients with liver metastases.
Topics: Breast Neoplasms; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Pyrimidines | 1963 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Dihydrouracil De | 2003 |
A case of chest wall recurrence of breast cancer treated with paclitaxel weekly, 5'-deoxy-5-fluorouridine, arterial embolization and chest wall resection.
Topics: Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Em | 2003 |
[A case of advanced breast cancer with multiple lung, bone and lymph node metastases successfully treated with 5'-DFUR alone].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; | 2003 |
Positive response to oral chemoendocrine combination therapy using 5"-deoxy-5-fluorouridine for locally advanced breast cancer with carcinomatous pleurisy: report of a case.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Therapy, Combination; | 2003 |
[A case of breast cancer with lung and bone metastasis treated successfully by oral combination chemotherapy of 5'-deoxy-5-fluorouridine and cyclophosphamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, | 2003 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2004 |
[A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
[Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combine | 2004 |
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 2004 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
[Effective reduction of elevated tumor markers by exemestane--a 12-year follow-up of a case of bone metastatic breast cancer].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2005 |
[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2005 |
[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2005 |
Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Respons | 2005 |
[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabin | 2005 |
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Clinical Trials, | 2005 |
Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cytarabi | 2006 |
Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Cell Cycle; Cell Line, Tumo | 2006 |
5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Caspase 7; Cell Cycle; Cell Proliferat | 2006 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
5-Fluorouracil incorporation in DNA of human breast carcinoma cells.
Topics: Breast Neoplasms; Cell Line; DNA Replication; DNA, Neoplasm; Female; Floxuridine; Fluorouracil; Huma | 1982 |
The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man.
Topics: Breast Neoplasms; Cell-Free System; Cytosol; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Humans | 1981 |
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine; | 1983 |
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female; | 1983 |
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Drug Administration Schedule; Drug Ev | 1984 |
[Phase II study of FF-705 by Clinical Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Drug Administratio | 1984 |
Uracil enhancement of 5-fluorodexoyuridine incorporation into human breast carcinoma deoxyribonucleic acid.
Topics: Breast Neoplasms; Cells, Cultured; DNA, Neoplasm; Female; Floxuridine; Humans; RNA, Neoplasm; Uracil | 1984 |
[Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Femal | 1984 |
Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Floxur | 1980 |
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1995 |
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Topics: Antineoplastic Agents; Biological Availability; Breast; Breast Neoplasms; Cell Communication; Cell D | 1995 |
[A case of recurrent breast cancer responding to combination therapy with mitoxantrone (MIT), 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1994 |
[A case of complete response of breast cancer with pulmonary metastases to combination therapy of 5'-DFUR and MPA].
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Floxuridine; Humans; Lu | 1994 |
[A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; F | 1994 |
[A case of inflammatory breast cancer successfully treated with 5'-DFUR and MPA].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; Ma | 1994 |
[A histological observation after a short-term administration of 5'-DFUR and tamoxifen in patients with advanced breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
[A case of long surviving inflammatory breast cancer with bone metastasis, treated by intra-arterial infusion chemotherapy followed by extended mastectomy].
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Floxuridine; Humans; | 1993 |
[Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer].
Topics: Administration, Oral; Adult; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; | 1993 |
[A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective].
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; | 1993 |
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Female; Flow Cytometry; Floxurid | 1993 |
[Usefulness of contact thermography for the evaluation of chemotherapeutic effectiveness in breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1993 |
[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Ad | 1996 |
[Intra-arterial infusion chemotherapy for liver metastases from breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1996 |
[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 1996 |
Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Division; Dose-Response Relationshi | 1997 |
[A case of advanced breast cancer receiving combination therapy with 5'-DFUR and MPA with remarkable results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Combin | 1997 |
[Efficacy of combination chemotherapy of cyclophosphamide and 5'-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosp | 1997 |
[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1997 |
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Combined Mo | 1998 |
[Comparative study of 5'-DFUR administration of single time per day versus two or three times].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Sche | 1998 |
[A case of stage IV breast cancer showing long-term complete response to combination therapy with 5'-DFUR and MPA].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Ne | 1998 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, D | 1998 |
[Comparative study of 5'-deoxy-5-fluorouridine between older cancer patients versus younger cancer patients].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla | 1999 |
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis.
Topics: Affinity Labels; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Breast Ne | 1999 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
[Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Flox | 1999 |
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 1999 |
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1999 |
[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model].
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cachexia; Cell Division; Female; Floxuridine; Huma | 1999 |
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1999 |
[A case of intra-arterial infusion chemotherapy for liver metastases of breast cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, P | 1999 |
[Successful treatment of pleuritis carcinomatosa using combination therapy of 5'-DFUR, MPA and CPA as maintenance therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1999 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Ne | 2000 |
[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclop | 2000 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
[A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr | 2000 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Carcinoma, Duct | 2000 |
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother | 2000 |
[A case of advanced breast cancer that responded remarkably to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2000 |
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2000 |
[Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2001 |
Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Divisi | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidi | 2001 |
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2001 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; | 2001 |
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplasti | 2002 |
[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophospha | 2002 |
[A case of breast cancer with multiple bone metastases that responded remarkably to doxifluridine (5'-DFUR), cyclophosphamide (CPA), medroxyprogesterone acetate (MPA) and pamidronate disodium therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2002 |
[The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 2002 |
Thymidine labeling index of human breast carcinoma. Enhancement of in vitro labeling by 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Topics: Breast Neoplasms; DNA, Neoplasm; Female; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Met | 1977 |
Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cytarabine; Drug Administration Schedule; Drug Evaluation | 1979 |
[A case of advanced breast cancer responding to low-dose 5'-DFUR].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; | 1992 |
[Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Cyclophospha | 1992 |
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.
Topics: Breast Neoplasms; Cell Death; Cell Division; Cell Membrane; DNA Damage; DNA, Neoplasm; Female; Floxu | 1992 |
Interleukin-6 and 12-O-tetradecanoyl phorbol-13-acetate act synergistically in inducing cell-cell separation and migration of human breast carcinoma cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Alkaloids; Antibodies, Monoclonal; Breast Neoplasms; Carcino | 1991 |
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; | 1991 |
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop | 1991 |
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1991 |
[Combination therapy with 5'DFUR and MPA as a second line treatment for advanced/recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Floxuridine; | 1990 |
[The study of 5-FU levels and pyrimidine nucleoside phosphorylase (PyNPase) activity in human breast cancer tissue after administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Mid | 1990 |
[A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; F | 1990 |
Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.
Topics: Breast Neoplasms; Cell Line; Female; Floxuridine; Humans; Kinetics; Macromolecular Substances; Mathe | 1985 |
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line; Cell Survival; Decitabine; Deoxycytidine; Deoxyuridine; DN | 1986 |
Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
Topics: Acyltransferases; Antineoplastic Agents; Breast Neoplasms; Carbon Radioisotopes; Cell Line; Female; | 1987 |
[The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Floxuridine; Fluorouracil; | 1989 |
[Intracellular localization of halogenated drugs or molecules in cultured tumor cells. A study using ionic microscopy associated with an imaging processing system].
Topics: Breast Neoplasms; Bromodeoxyuridine; Cells, Cultured; Female; Floxuridine; Humans; Image Processing, | 1989 |
[Effect of combination chemotherapy of 5'-DFUR, cyclophosphamide and tamoxifen in a case of advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1989 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration | 1985 |
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarr | 1985 |
[Phase II study of 5'-DFUR (5'-deoxy-5-fluorouridine) by the Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla | 1985 |
[Diagnosis of minimal breast cancer by diagnostic hormonal treatment].
Topics: Adult; Androstanols; Breast; Breast Neoplasms; Female; Fibrocystic Breast Disease; Floxuridine; Huma | 1986 |
Phase II clinical evaluation of doxifluridine.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col | 1986 |
[Clinical trial of 5'-deoxy-5-fluorouridine in malignant tumors under cooperative study (phase II study)].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Floxuridine; | 1986 |
[Combination chemotherapy of human gastrointestinal and breast cancer xenografts in nude mice with 5'-deoxy-5-fluorouridine and mitomycin C].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female | 1986 |
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
Catheter perforation of the duodenum during hepatic artery chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Doxo | 1987 |
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans; | 1987 |
A phase II study of doxifluridine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans; | 1988 |
[Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridi | 1988 |
[Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colo | 1985 |
Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Female; Floxuridine; Gastroscopy; Humans; Infusions, Intra-Arterial; | 1985 |
Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; Leukemia L1210; Leuke | 1985 |
[Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Ev | 1985 |
Systemic chemotherapy of mammary carcinoma.
Topics: Amines; Antineoplastic Agents; Azirines; Azo Compounds; Breast Neoplasms; Caproates; Carbohydrates; | 1971 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).
Topics: Blood Cell Count; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Female; Floxuridin | 1971 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |
Evaluation of a cell-mediated cytotoxicity assay utilizing 125 iododeoxyuridine-labeled tissue-culture target cells.
Topics: Adult; AKR murine leukemia virus; Animals; Antigens, Neoplasm; Breast Neoplasms; Cell Line; Cells, C | 1973 |
The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
Topics: Adenoma, Islet Cell; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fl | 1965 |